Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Role of Antisecretory Factor in Curative Radiochemotherapy for Anal Carcinoma (SALFLAC)

22 avril 2022 mis à jour par: Peter Nygren, Uppsala University Hospital

A Randomized Phase 2 Double-blind Placebo-controlled Trial Investigating the Effect of Salovum™ and SPC-flakes on Radiochemotherapy Induced Toxicity in Curative Treatment of Anal Carcinoma

Curative radiochemotherapy (RCT) for anal carcinoma (AC) is associated with considerable acute and long-term toxicity. The acute toxicity derives from the combined effects of radiation and chemotherapy and is dominated by localized skin mucositis, diarrhoea and pain from radiation and nausea, fatigue, anemia/leukopenia, diarrhoea and general skin dryness from chemotherapy. Cholera induced diarrhoea, as well as other forms of diarrhoea-inducing agents, has been shown to elicit a stimulated, endogenous production of a protein, named "antisecretory factor" (ASF). This protein has been chemically characterized in detail. ASF acts by modulating secretion of water and ions but also counteracts inflammatory processes. With this background the present study will investigate if induction of endogenous ASF by intake of SPC-flakes might be beneficial in AC patients to prevent RCT induced adverse events (AEs) and if administration of ASF from Salovum provides additional benefit (explorative).

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Description détaillée

Curative RCT for AC is associated with considerable acute and long-term toxicity.

The acute toxicity derives from the combined effects of radiation and chemotherapy and is dominated by localized skin mucositis, diarrhoea and pain from radiation and nausea, fatigue, anemia/leukopenia, diarrhoea and general skin dryness from chemotherapy. These adverse effects are treated symptomatically with mostly modest effect and sometimes leads to the need for in-patient care and temporary stop of the RCT. Long-term toxicity is caused by radiation fibrosis and is dominated by impaired anal sphincter function leading to faeces incontinence, pelvic pain and reduced sexual function. Thus, new ways to efficiently counteract the RCT induced adverse effects are urgently needed.

Cholera induced diarrhoea, as well as other forms of diarrhoea-inducing agents, has been shown to elicit a stimulated, endogenous production of a protein, named "antisecretory factor" (ASF). This protein has been chemically characterized in detail. ASF acts by modulating secretion of water and ions but also counteracts inflammatory processes . ASF is also produced by hens fed on a diet of fermented grains or a specific diet of sugars and amino acids, leading to an accumulation of the ASF protein in the egg yolk. Spray dried yolk in the form of a powder is commercialized as Salovum registered by the EU authorities as "Food for specific medical purposes", i e is not adrug from a regulatory perspective.

Salovum rapidly increase the plasma (P-) ASF-concentration. Another way to increase ASF and, thus, to achieve benefit, is to induce its production/conversion by ingestion of oat flakes, specially processed (similar to malting) to contain the proper mix of sugars and amino acids. Such flakes are also commercially available (named SPC flakes) as "Food for specific medical purposes" and has been recommended or considered for a number of secretory pathological conditions, e g for treatment of Mb Meniére.

With this background the present study will investigate if induction of endogenous ASF by intake of SPC-flakes might be beneficial in AC patients to prevent RCT induced adverse events (AEs) and if administration of ASF from Salovum provides additional benefit (explorative).

Type d'étude

Interventionnel

Inscription (Anticipé)

38

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Histologically confirmed diagnosis of AC irrespective of tumour p16-status.
  3. Planned for curative RCT according to national care programme schedule B
  4. WHO performance status of 0 or 1.
  5. For patients planned for schedule C, they must be unsuitable for or not consenting to participation in the SWANCA trial.
  6. Able to understand study information and questionnaires and provide signed informed consent.

Exclusion Criteria:

  1. Patients with stoma.
  2. Contraindications to the investigational product, e g known or suspected hypersensitivity to the investigational products or expected inability to their use in accordance with the protocol.
  3. Contraindications to curative RCT in accordance with AC national care programme.
  4. Lack of suitability for participation in the study, e g expected difficulties to follow the protocol procedures, as judged by the investigator.
  5. Prior exposure to Salovum or SPC-flakes.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: SPC-flakes with or without Salovum
SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
Salovum and SPC-flakes are foods approved for specific medical purposes.
Comparateur placebo: SPC-flakes placebo with or without Salovum placebo
SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum placebo egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
Salovum and SPC-flakes are foods approved for specific medical purposes.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.
Délai: Through study completion, approximately 6 months
Treatment related toxicity
Through study completion, approximately 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence and severity of other AEs according to CTCAEv5.0 during and up to 6 months after RCT.
Délai: Through study completion, approximately 6 months
Other treatment related toxicity
Through study completion, approximately 6 months
Change from baseline in patient reported hQoL and abdominal symptoms assessed by EORTC QLQ- 30 and the ANL27 subscale questionnaires as well as the Bristol Stool Form Scale.
Délai: Through study completion, approximately 6 months
PROMS
Through study completion, approximately 6 months
Increase in plasma (P)-ASF concentration from baseline to the day of start of RCT and to the end of treatment.
Délai: Days -1, 6 and 42
Pharmacodynamic outcome and compliance check
Days -1, 6 and 42
Relationships between P-ASF concentration, biomarkers reflecting inflammation and adverse events.
Délai: Through study completion, approximately 6 months
Biomarker assessments
Through study completion, approximately 6 months
Differences in primary and secondary endpoints between Salovum and placebo subgroups.
Délai: Through study completion, approximately 6 months
Assessment of added value of Salovum
Through study completion, approximately 6 months
Tumour response rate according to RECIST v1.1 and clinical examination at 2, 3 (radiology) and 6 months after stop of RCT.
Délai: Through study completion, approximately 6 months
Assessment of benefit, if any, from study products on clinical outcome
Through study completion, approximately 6 months
Disease free and overall survival at 3 and 6 months after stop of RCT.
Délai: At 3 and 6 months after stop of treatment
Assessment of benefit, if any, from study products on clinical outcome
At 3 and 6 months after stop of treatment

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.
Délai: Through study completion, approximately 6 months
Adverse effects from study products
Through study completion, approximately 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Anticipé)

1 juin 2022

Achèvement primaire (Anticipé)

1 décembre 2023

Achèvement de l'étude (Anticipé)

1 mars 2024

Dates d'inscription aux études

Première soumission

14 avril 2022

Première soumission répondant aux critères de contrôle qualité

22 avril 2022

Première publication (Réel)

28 avril 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 avril 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 avril 2022

Dernière vérification

1 avril 2022

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

To be considered

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner